Advanced Enzyme Technologies Limited filed an intimation on 4 August 2026, notifying exchanges that it will host a conference call for analysts and investors on Wednesday, 12 August 2026 at 4:00 p.m. IST to discuss its un-audited financial results for the quarter ended 30 June 2026.
Key Highlights
- The company has scheduled an analyst and investor conference call for Wednesday, 12 August 2026 at 4:00 p.m. IST to cover Q1 FY27 un-audited financial results.
- The intimation was filed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- Company Secretary and Head of Legal Sanjay Basantani signed and submitted the filing to both BSE (Scrip ID: 540025) and NSE (Scrip Code: ADVENZYMES).
- Call details have also been uploaded on the company's official website, as stated in the filing.
About the Company
Advanced Enzyme Technologies Limited (NSE:ADVENZYMES), headquartered in Mumbai, is one of India's largest enzyme manufacturers, operating across human healthcare, animal nutrition, baking, and industrial applications. The company runs multiple production facilities and exports enzyme products to over 45 countries. It operates within the specialty chemicals and biotechnology segment of the Indian pharmaceutical and agri-sciences sector.
Announcement in Detail
In a filing submitted on 4 August 2026 to both the National Stock Exchange of India and BSE Limited, Advanced Enzyme Technologies Limited informed the exchanges that it will convene a conference call specifically for analysts and institutional investors. The call is scheduled for Wednesday, 12 August 2026, beginning at 4:00 p.m. Indian Standard Time. The purpose of the call, as stated in the filing, is to discuss the company's un-audited financial results for the quarter ended 30 June 2026, which corresponds to the first quarter of financial year 2027.
The intimation has been submitted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which requires listed companies to disclose events likely to be of interest to investors in a timely manner. The filing was signed by Sanjay Basantani, Company Secretary and Head of Legal, and the company confirmed that additional details pertaining to the call have been uploaded to its official corporate website.
Impact on Investors
Investors will note that this filing is a procedural disclosure and does not itself contain any financial figures or results for the June 2026 quarter. The conference call on 12 August 2026 is the forum at which management will present and discuss the un-audited Q1 FY27 numbers for the first time. Shareholders will observe that the call format is standard practice for listed companies and provides an opportunity to hear management commentary on quarterly performance.
The filing shows no change in shareholding, dividends, or corporate actions at this stage. Investors seeking to access the call details are directed to the company's official website, where further particulars have been uploaded as referenced in the exchange filing.
Sector / Market Context
India's enzyme manufacturing sector has grown steadily as demand rises from food processing, pharmaceuticals, and animal feed industries. According to industry data, the global enzyme market is valued in the billions of dollars, with Indian companies increasingly capturing export share in specialised segments such as baking enzymes and nutraceuticals. SEBI's Regulation 30 framework, under which this filing is made, mandates timely disclosure of investor-relevant events, ensuring that retail and institutional participants receive material information through formal exchange channels before it is discussed in analyst forums.